In addition, CLL cells with trisomy 12 potentially develop primary resistance to venetoclax due to specific alterations in the IRF4/NOTCH2 axis, and the initial treatment phase has been unsatisfactory (42, 43), suggesting that we should choose another appropriate drug if trisomy 12 of CLL cells occurs. Here, IRF4 is linked to B-cell chronic lymphocytic leukemia.